Lung Cancer
From the Journals
Smoking neglected in patients with PAD
Conference Coverage
Neoadjuvant TKI for advanced NSCLC falls short
MUNICH – Erlotinib for stage IIIA (N2) NSCLC may increase progression-free survival, but clinical benefits fall...
Conference Coverage
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
Conference Coverage
ALTA-1L: Brigatinib beats crizotinib for PFS in ALK-positive NSCLC
The ALTA-1L trial showed a 51% reduction in progression-free survival with brigatinib versus crizotinib in ALK-positive NSCLC.
Conference Coverage
Adherence to follow-up lung cancer screening not optimal
Patients at high risk for lung cancer are recommended to have an annual low-dose CT scan after a negative baseline scan.
News
FDA approves oral dacomitinib for some metastatic NSCLC
The drug has a recommended dose of 45 mg once daily with or without food.
Conference Coverage
PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLC
TORONTO – Updated PACIFIC trial results show that durvalumab provides first major OS, PFS advance for stage III NSCLC in decades.
From the Journals
Capmatinib plus gefitinib overcomes EGFR resistance in NSCLC
In patients with a high level of MET amplification, responses were more common, with almost half of the NSCLC patients responding.
From the Journals
More frequent CT surveillance in NSCLC doesn’t improve survival
A study looks at the impact of surveillance frequency on NSCLC survival.
News
FDA grants full approval to pembrolizumab for advanced NSCLC
The checkpoint inhibitor is approved with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC, with no...